about
Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.Niche-based screening identifies small-molecule inhibitors of leukemia stem cellsRole of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.Core Circadian Clock Genes Regulate Leukemia Stem Cells in AMLModeling the human 8p11-myeloproliferative syndrome in immunodeficient mice.Human short-term repopulating cells have enhanced telomerase reverse transcriptase expression.Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6-dependent manner.Expression of P190 and P210 BCR/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage.IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.Power cut: inhibiting mitochondrial translation to target leukemiaAgonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cellsNatural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK CellsArrayed molecular barcoding identifies TNFSF13 as a positive regulator of acute myeloid leukemia-initiating cellsFLT3N676K drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesisCXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia
P50
Q30252566-5CC401EC-FEC2-4811-B685-270C9B3D1742Q33563509-55D4F2EB-3E52-4603-94F7-5ABDAFCE6DACQ34348631-D0C73162-F68F-4FAB-89D1-4B96C6CEDE11Q34483086-FB5A4602-D6C5-4B85-B524-A874EF32DF10Q35044993-1701D010-720B-4522-87C5-CAB6A0012218Q35116967-141E6DD5-A9C2-48E8-8C57-E215CAFB3A7FQ36008395-4B2A4A31-1529-41DF-82B1-41D6FF4F1F81Q36783304-A2A0FF62-1384-4107-A0BF-FF65621A6FFCQ39862996-A7A243C8-4967-4FB9-826B-66949C677AD8Q45861253-C7472CF2-67B1-4EE0-A27B-4AC5138A14D1Q45870922-71E581C3-95C3-4C0D-8A49-16045BAC9208Q46168248-819719C5-0819-4706-A475-A9FF8EDE6194Q51514760-9FAFE463-016D-40FA-B6B0-71E34F2B53A2Q52714487-D95BBC3A-AEB9-4C96-B2AB-279772208619Q52735344-A2D829C3-476A-4F01-AF35-676C3DD070ADQ53470550-1AE55BB6-B85A-4B37-BA30-214D7FA21084Q82557115-085284DB-A7FF-4D89-9066-DAFCE26631E4Q89777451-E2AE9F00-F989-4272-B547-F2A5007A184AQ91082724-A9C00FA0-F4C5-45C4-9946-FAD4C47993D0Q92022416-3850E35F-F8B2-4847-84AE-0653B197CCECQ92887052-2D77EEDE-3B2A-4BDB-868C-8BD5F242660BQ95923950-4BA0BE6B-8BEC-482D-8529-A81AD0768391
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marcus Järås
@ast
Marcus Järås
@en
Marcus Järås
@es
Marcus Järås
@nl
type
label
Marcus Järås
@ast
Marcus Järås
@en
Marcus Järås
@es
Marcus Järås
@nl
prefLabel
Marcus Järås
@ast
Marcus Järås
@en
Marcus Järås
@es
Marcus Järås
@nl
P106
P31
P496
0000-0003-4080-7055